Morepen Laboratories files first US ANDA for sitagliptin tablets
In short
Morepen Laboratories filed its first US ANDA for sitagliptin tablets in three strengths. The filing marks its move into finished-dose development and regulatory filings in the US market.
This matters because it could open a new business path for the company in the US. The reporting does not say when approval might come or list the strengths.
What the reporting says
Morepen Laboratories filed its first US ANDA for sitagliptin tablets in three strengths, marking an entry into integrated finished-dose development and regulatory filings in the US market. The reporting does not state the strengths or any approval timeline. The filing could expand the company’s US presence, but the outcome is not yet known.
Why it matters
Morepen Laboratories filed its first US ANDA for sitagliptin tablets in three strengths, according to the source summary. The filing marks entry into integrated finished-dose development and regulatory filings in the US market. The reporting does not specify the strengths or say whether approval has been granted. The immediate business impact is potential US market entry.